This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Demolis, J.-L. Articles by Jaillon, P. Search for Related Content PubMed PubMed Citation Articles by Demolis, J.-L. Articles by Jaillon, P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

(Circulation. 1996;94:1592-1599.)
© 1996 American Heart Association, Inc.

Articles

Influence of Dofetilide on QT-Interval Duration and Dispersion at Various Heart Rates During Exercise in Humans

Jean-Louis Demolis, MD; Christian Funck-Brentano, MD, PhD; Jacques Ropers, PharmD; Mathieu Ghadanfar, MD; Donald J. Nichols, PhD; Patrice Jaillon, MD

the Clinical Pharmacology Unit, Saint-Antoine University Hospital, Paris, France; the Pfizer Clinical Research Group (M.G.), Paris La Defense, France; and Pfizer Central Research (D.J.N.), Sandwich, United Kingdom.

Correspondence to Patrice Jaillon, Unite de Pharmacologie Clinique, Hopital Saint-Antoine, 184 rue du Faubourg Saint-Antoine, 75012 Paris, France.

Background The objective of this study was to assess the influence of heart rate on QT-interval duration and dispersion during administration of the new selective potassium-channel blocker dofetilide in normal subjects.

Methods and Results Dofetilide 0.25 and 0.75 mg was administered for 4 days to 12 subjects in a randomized-sequence, double-blind, three-period, placebo-controlled, crossover study. QT-RR pairs were measured on study day 4 over a wide range of RR intervals obtained at rest and during an exercise test. QT-interval durations were calculated at seven predetermined RR intervals ranging from 400 ms (150 bpm) to 1000 ms (60 bpm) by use of monoexponential nonlinear curve fitting. QT_max and QT_min were calculated similarly, and QT-interval dispersion was measured as QT_max-QT_min at each predetermined RR interval. Minimal effects were found with 0.25 mg dofetilide. Two hours after administration of 0.75 mg dofetilide, QT interval was prolonged by 16.7±8.7% at a heart rate of 60 bpm (P<.01) and by 7.4±8.2% at a heart rate of 150 bpm (P<.05). QT prolongation at a heart rate of 150 bpm was less pronounced than at lower heart rates. Neither placebo nor dofetilide at either dose significantly increased QT-interval dispersion at any heart rate.

Conclusions Dofetilide increases QT-interval duration but does not increase QT-interval dispersion in healthy subjects. QT-interval prolongation remains significant at high heart rates, although some degree of reverse rate dependence is observed at high concentrations.

Key Words: antiarrhythmia agents • drugs • potassium

This article has been cited by other articles:

				S. M. Al-Khatib, N. M. A. LaPointe, J. M. Kramer, and R. M. Califf What Clinicians Should Know About the QT Interval JAMA, April 23, 2003; 289(16): 2120 - 2127. [Abstract] [Full Text] [PDF]

				B. Brendorp, H. Elming, L. Jun, L. Kober, C. Torp-Pedersen, and for the DIAMOND Study Group Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure Eur J Heart Fail, March 1, 2002; 4(2): 201 - 206. [Abstract] [Full Text] [PDF]

				M. Lei, P. J Cooper, P. Camelliti, and P. Kohl Role of the 293b-sensitive, slowly activating delayed rectifier potassium current, iKs, in pacemaker activity of rabbit isolated sino-atrial node cells Cardiovasc Res, January 1, 2002; 53(1): 68 - 79. [Abstract] [Full Text] [PDF]

				M.-D. Drici Influence of gender on drug-acquired long QT syndrome Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K41 - K47. [Abstract] [PDF]

				J. P. Mounsey and J. P. DiMarco Dofetilide Circulation, November 21, 2000; 102(21): 2665 - 2670. [Full Text] [PDF]

				M. Zabel, M. R. Franz, T. Klingenheben, B. Mansion, H.-P. Schultheiss, and S. H. Hohnloser Rate-dependence of QT dispersion and the QT interval: comparison of atrial pacing and exercise testing J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1654 - 1658. [Abstract] [Full Text] [PDF]

				R. Rouet, S. Picard, C. Libersa, M. Ghadanfar, C. Alabaster, and J.-L. Gerard Electrophysiological Effects of Dofetilide in an In Vitro Model of "Border Zone" Between Normal and Ischemic/Reperfused Myocardium Circulation, January 4, 2000; 101(1): 86 - 93. [Abstract] [Full Text] [PDF]

				S. K. Doshi and B. N. Singh Reviews: Pure Class III Antiarrhythmic Drugs: Focus on Dofetilide Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(4): 237 - 247. [PDF]

				B. Houltz, B. Darpo, K. Swedberg, P. Blomstrom, H.J.G.M. Crijns, S.M. Jensen, E. Svernhage, and N. Edvardsson Comparison of QT dispersion during atrial fibrillation and sinus rhythm in the same patients, at normal and prolonged ventricular repolarization Europace, January 1, 2000; 2(1): 20 - 31. [Abstract] [PDF]

				R. F. Bosch, R. Gaspo, A. E. Busch, H. J. Lang, G.-R. Li, and S. Nattel Effects of the chromanol 293B, a selective blocker of the slow, component of the delayed rectifier K+ current, on repolarization in human and guinea pig ventricular myocytes Cardiovasc Res, May 1, 1998; 38(2): 441 - 450. [Abstract] [Full Text] [PDF]